The Economics of Rarity: Why We Spend Trillions on Nothing and Hesitate to Fund What Matters

Value, Misalignment, and the Strange Economics of Modern Life

Every society reveals its priorities through the way it spends money, and modern life offers a revealing paradox: we routinely treat rare-disease research as expensive, yet we casually burn hundreds of billions of dollars each year on things that produce no lasting benefit at all. We call this “consumer choice,” but at a systems level it’s really a form of misalignment—an enormous gap between where dollars flow and where value comes from.

This essay is about that gap. It’s about what happens when we compare the cost-benefit of rare-disease research—one of the highest-value, highest-return forms of scientific investment—with the money we send into literal landfills, casinos, subscription black holes, and purchasing cycles that generate nothing but depreciation. The contrast is sharp enough to feel like satire, yet every figure is real. It raises a simple, profound question: if the money is already flowing, why isn’t it flowing toward outcomes that extend healthy life, reduce suffering, accelerate science, and strengthen the public good?

We often think of rare-disease research as “boutique science,” serving populations too small to matter, or too medically complex to justify the cost. But at the systems level, rare diseases are neither small nor marginal. More than 300 million people worldwide live with one. Many conditions begin in childhood and impose staggering lifetime burdens—emotional, economic, and societal. And when a breakthrough does occur, it does something very few investments can claim: it produces decades of health, productivity, and downstream scientific tools that benefit not only patients in that tiny cohort but sometimes entire fields of medicine.

Against that backdrop, something extraordinary comes into focus: at the very same moment we debate every dollar spent on gene therapy platforms, newborn genomic screening, or natural-history registries, society casually disposes of sums that could cure dozens of diseases, end the diagnostic odyssey for millions of families, and build scientific infrastructure that would pay for itself many times over. We simply spend that money elsewhere—on items and behaviors with no compounding value, no health benefit, no scientific uplift, and often negative returns.

There is a story here about human psychology. A story about how markets shape our sense of value. And a story about how systems drift, not because people are malicious or indifferent, but because the feedback loops are invisible. Rare-disease research offers a different kind of feedback loop: one that is moral, scientific, economic, and profoundly generative. It shows us what good systems look like. It shows us what aligned investments can do.

This essay is not an argument for austerity or moralizing consumption. It is an attempt to show, with clarity and fairness, what becomes possible when we see where our dollars already go—and what they could accomplish if redirected by even the smallest fraction. The point is not guilt. The point is possibility.

The Hidden Cost of Rarity: A Quiet Billion-Dollar Burden

Rare diseases often sound statistically trivial, yet together they form one of the most consequential—and costly—public health challenges of our time. In the United States alone, the total economic burden of rare diseases is measured in the trillions. Families face repeated hospitalizations, years of specialist visits, well-intentioned but inconclusive tests, and disabling symptoms that erode educational progress, employment, mobility, and independence. Even when treatments exist, diagnostic delays can stretch to half a decade or more, compounding medical costs and narrowing therapeutic windows.

What makes rare diseases unusual is the combination of scale and specificity. Each individual condition affects relatively few people, which obscures the fact that the collective burden is enormous. Meanwhile, the underlying biology is often clean and mechanistic—a single gene, a single enzyme, a single misfolded protein. This creates unusually clear windows for scientific progress. Many major breakthroughs in genetics, molecular biology, and gene therapy first emerged from attempts to understand or treat rare diseases. These are the fields where new vectors, new delivery systems, and new platforms are forged.

From a systems perspective, that is the paradox: the burden is immense, the scientific leverage is high, the potential societal ROI is huge—and yet rare-disease research receives a fraction of the funding that flows effortlessly into disposable consumption. The mismatch is not subtle. It is structural. And because it is structural, it is correctable.

Which brings us to the other half of the equation: if rare-disease research offers some of the highest-value investments society can make, what are the lowest-value uses of money we habitually support?

That is the turn we take next.

What Society Already Spends on Nothing

Every economy contains two currents: the obvious one, where dollars are exchanged for things we know we value, and a second current—less visible, but vastly larger—where money circulates in ways that create no lasting benefit. Economists call this “nonproductive expenditure.” A systems thinker might call it a form of entropy: money converted into short-lived experience, wear, waste, or damage with no durable return.

When we compare this second current to the funding levels of rare-disease research, the contrast is startling. Consider just a few of the largest categories.

Lottery Tickets: A Regressive Black Hole Americans spend more than $100 billion per year on lottery tickets. It is the single largest form of gambling in the country. The return is mathematically negative—every ticket is purchased with the expectation of losing money. Yet it persists because people buy hope, stories, superstition, and the tiny thrill of possibility. From a systems perspective, however, this river of money flows away from public good into a sink of diminishing returns. The same annual sum could fund genome sequencing for every newborn in America three times a year, laying the foundation for early diagnosis of hundreds of conditions.

Food Waste: A Quarter-Trillion Dollars in the Trash The United States throws away roughly $220 billion worth of food each year. This includes spoiled groceries, uneaten restaurant meals, and produce discarded for aesthetic blemishes. All of it represents resources extracted, transported, refrigerated, displayed, purchased—and then forgotten. Food waste is not simply inefficient; it is negative-sum. It wastes farmland, emits greenhouse gases, and imposes municipal disposal costs. Yet it continues because the incentives are diffuse and the loss is invisible at the household level.

The Phone-Upgrade Churn We refresh our phones every year or two, often for reasons that have nothing to do with function. Americans spend an estimated $50 to $60 billion annually replacing devices that still work. This cycle produces little to no incremental productivity but generates staggering e-waste, resource extraction, and short-lived consumer satisfaction. It is consumption as habit rather than consumption as value.

Disposable Vapes and the Economics of Pure Ephemera The disposable vape market—roughly $8 to $10 billion per year in the U.S.—creates a product designed to be used for a week and thrown away. No savings, no durable good, no compounding return. Each device is a concentrated packet of plastic, lithium, and circuitry destined for a landfill. Rare-disease research is often labeled as too expensive; meanwhile an entire industry has grown around turning valuable materials into trash on purpose.

Unused Subscriptions: The Silent Siphon Gyms, apps, streaming platforms, cloud storage, newsletters—together, Americans spend roughly $50 billion a year on subscriptions they do not use. This is the digital equivalent of a leaky pipe: dollars trickling out month after month, invisible because the increments are small. But in aggregate, this is enough money to fund every stalled rare-disease clinical trial in the U.S. with room to spare.

Sugary Drinks: A Health-Destructive Line Item Over $60 billion per year goes into sugar-sweetened beverages. Unlike modest indulgences (dessert, coffee, wine), sugary drinks have a quantifiable negative ROI: they increase long-term healthcare costs, reduce quality of life, and contribute to diseases the medical system must later try to control. This is not moral judgment—it is simply a systems fact. An expenditure that produces downstream medical burden is the definition of negative return.

Gambling Losses: The Designed Drain Americans lose roughly $60 billion per year at casinos, slots, and online gambling. These losses are not accidental; they are engineered by design. Unlike entertainment spending, which at least produces experience, gambling losses produce no stable value and can directly cause financial harm. Picture what $60 billion could do if redirected to gene therapy research, pediatric care networks, or the architecture of scientific discovery. Picture the children whose lives would be transformed.

A Landscape of Structural Waste What unites these categories is not judgment, but pattern: enormous sums of money flowing toward outcomes with no compounding benefit, no societal uplift, and in many cases, measurable harm. These expenditures are normalized because they are distributed across millions of individuals, each acting independently, without any awareness of the collective total. No individual sees themselves as the system. But the system sees all of us.

From a Humboldt’s Home perspective, what matters is that the money already exists. We are not talking about raising new funds, imposing austerity, or limiting personal freedom. We are talking about recognizing that society already spends enough on “nothing” to fund rare-disease research at levels that would fundamentally reshape human health for generations.

Which brings us to the other half of the comparison: what rare-disease research produces in return—and why even small redirections of wasteful spending can create extraordinary value.

What the Same Money Buys in Rare-Disease Research

To appreciate the magnitude of this contrast, we need to look at what rare-disease research actually produces. Here the systems story flips: instead of dollars evaporating into zero-value consumption, we see money transformed into life-years, scientific tools, cured children, new therapeutic platforms, and cost savings that compound for decades.

Rare diseases, for all their diversity, often share a single defining feature: clear, mechanistic causes. A missing enzyme. A broken gene. A misfolded protein. These sharp edges of biology make rare diseases uniquely suited to breakthrough science. When we invest in them, we are not funding mysteries—we are funding solvable problems. And because the biology is often clean, the tools we develop to solve them become the scaffolding for treating far more common diseases.

Consider the following examples, which reveal what every dollar of rare-disease investment can unlock.

Gene Therapies That Replace Lifetimes of Medical Costs Treatments like the one-time gene therapy for spinal muscular atrophy (SMA) carry high upfront costs, but these investments displace millions of dollars in lifetime care. Many children treated with SMA gene therapy avoid ventilators, wheelchairs, or the loss of function that once seemed inevitable. A therapy costing a few million dollars up front avoids five million or more in downstream medical spending and restores decades of healthy life.

Contrast this with lottery spending: one year of U.S. lottery purchases could provide curative gene therapies to 50,000 children—a scale of healing unprecedented in human history.

CRISPR Treatments That Redefine What Medicine Can Do The first CRISPR-based therapy approved for sickle cell disease demonstrates how rare-disease research accelerates the entire field of genome editing. In trials, patients who had endured a lifetime of pain crises experienced nearly complete remission. These therapies don’t just treat symptoms—they rewrite the biological script.

And because the underlying tools (CRISPR editing, conditioning regimens, delivery systems) are platform technologies, they create uplift for common diseases like cancer, heart disease, and autoimmune disorders. A few billion redirected from food waste could expand CRISPR’s medical reach by an order of magnitude.

Newborn Genomic Screening That Prevents Lifelong Disability Many rare diseases cause irreversible damage if untreated for even a few weeks after birth. Yet sequencing a newborn’s genome costs less than an average family spends on a single restaurant outing. With newborn genomic screening, conditions like SCID, AADC deficiency, and metabolic disorders can be identified before symptoms appear, enabling interventions that prevent disability entirely.

One year of U.S. spending on sugary beverages could provide universal newborn genome sequencing for the entire country six times over, eliminating thousands of missed diagnoses.

Enzyme-Replacement and Modulator Therapies That Create Lifetimes of Value Cystic fibrosis modulators, born from decades of rare-disease research, have added 15–20 years of life expectancy for many patients. These drugs also reduce hospitalizations, prevent lung transplants, and preserve the ability to work, study, and live independently. The economic return is measured not only in avoided medical costs, but in preserved human potential.

Even a tiny fraction of the money wasted on unused subscriptions each year could dramatically expand access, accelerate next-generation research, and reach children who still lack effective therapies.

Scientific Platforms That Benefit Everyone Perhaps the most overlooked benefit is that rare-disease research builds the scaffolding of future medicine. The Human Genome Project was not a rare-disease initiative, but nearly all of its early successes came from understanding and treating rare monogenic conditions. The same is true for:

• viral vectors used in gene therapy
• genome-wide association studies
• AAV delivery systems
• RNA therapeutics
• small-molecule correctors of protein folding
• cellular reprogramming methods
• natural-history registries
• phenotype–genotype mapping

Every dollar spent on rare diseases builds scientific platforms that ripple outward.

A Dollar Spent on Rare-Disease Research Is a Dollar That Compounds Unlike lottery tickets, sugary drinks, or gambling losses, investments in rare-disease research compound over time. They generate new therapies, new diagnostics, and new technological capabilities. They create value not only for a small cohort of patients, but for entire families, communities, and, in many cases, the broader medical landscape.

And here is the core insight: it takes only minuscule redirections of wasted spending to produce monumental gains. If the United States redirected just 1% of annual structural waste—roughly $5 to $6 billion—we could accelerate cures for hundreds of conditions, end the diagnostic odyssey for millions, and dramatically expand the reach of genomic medicine.

That brings us to the deeper systems explanation: why rare-disease research produces outsized returns, and why these returns reveal something essential about how value is created.

Why Rare-Disease Research Delivers Outsized Value

There is a structural reason why rare-disease research punches far above its statistical weight: rare diseases sit at the crossroads of clean biology and high human impact. They illuminate the deepest layers of the genome, the sharpest edges of molecular function, and the most mechanistic forms of illness. When we invest in understanding them, we often uncover mechanisms that apply to thousands or millions of people.

This is not an accident. It is a property of complex systems. In any network—ecological, economic, biological, or technological—the greatest leverage is often found in the smallest, most tightly coupled nodes. Rare diseases are those nodes.

Rare Diseases Clarify Cause and Effect Because many rare diseases stem from a single genetic mutation, they provide some of the most straightforward biological models in medicine. When a gene fails to produce an enzyme, and that enzyme’s absence leads directly to a recognizable disorder, the path from cause to effect is unusually clear. Intervening at that point teaches us how molecular pathways operate in all humans, not just in the rare subset.

Lotteries teach us nothing. Food waste teaches us nothing. But rare-disease research teaches us everything about how life works.

They Accelerate the Development of Platform Technologies

CRISPR. AAV vectors. Adenine base editors. mRNA therapeutics. Organoids. Induced pluripotent stem cells. Every one of these technologies owes a piece of its early development to the effort to understand or treat rare diseases. These are not boutique tools. They are the transformation engines of 21st-century medicine.

An additional $5 billion—a tenth of annual gambling losses—could multiply the pace of vector development, reduce manufacturing costs, and expand the safety profile of these platforms. That is the difference between a handful of gene therapies and an entire generation of them.

They Reveal Hidden Connections: The Small Populations–Big Impact Paradox The surprising truth: treating small populations often benefits large ones. This is because rare diseases are biological “boundary conditions”—extreme cases that illuminate general rules. When we understand how one genetic mutation disrupts a pathway in 500 people, we learn something about how that pathway behaves in 500 million.

Wasteful consumption has no such multiplier. It produces nothing downstream except more waste.

They Reduce Long-Term Healthcare Costs No category of spending yields a clearer cost-benefit ratio than interventions that prevent lifelong disability. Every cured or stabilized rare disease represents decades of avoided costs: hospitalizations, mobility devices, assistive care, lost wages, missed schooling, early mortality. The financial burden is enormous, but the invisible burden—the grief, exhaustion, and shattered expectations carried by families—is larger still.

Every one-time gene therapy that averts these losses produces savings that dwarf its sticker price. Investments in rare-disease research therefore create returns that are not only economic, but moral.

They Provide Compounding Social Value In finance, compounding is the most powerful force in the universe. Rare-disease research produces compounding in biology: knowledge gained early in the research process accumulates into better diagnostics, smarter interventions, more precise biological models, and therapies that leapfrog into neighboring fields.

Contrast this with the money we lose to structural waste. Food that spoils. Gadgets that are replaced before they break. Casino losses that disappear without a trace. These expenditures not only fail to compound—they anti-compound, evaporating into financial and environmental entropy.

They Align With the Deepest Values of a Society At its heart, rare-disease research reflects a commitment to the dignity of every person, regardless of how many people share their diagnosis. It is a form of solidarity across difference, a recognition that statistical rarity does not diminish human worth. Societies reveal their deepest values not through what they say they believe, but through what they are willing to invest in when nobody is watching.

And so we return to the paradox: we routinely spend trillions on things that produce no lasting benefit, yet treat rare-disease research as an extravagance.

The next section widens the lens. It looks back over the last 25 years to see how far rare-disease research has come, what technologies it has created, and what lessons this trajectory offers for the next generation of breakthroughs.

Historical Lens — Twenty-Five Years of Breakthroughs, Misalignments, and What We Learned

Looking back over the last quarter-century reveals a striking contrast between the pace of scientific progress in rare-disease research and the sluggishness of societal investment. Beginning in the late 1990s, the Human Genome Project opened the door to identifying the genetic roots of thousands of conditions. By 2003, the reference genome was complete, and the cost of sequencing had begun its dramatic fall. Each drop in price expanded our understanding of rare diseases, transforming them from medical mysteries into mechanistically defined conditions.

In the mid-2000s, viral vector research matured, with AAV-based approaches showing early promise. These tools—developed initially for tiny patient populations—formed the backbone of today’s gene therapy revolution. Treatments for spinal muscular atrophy, inherited retinal diseases, and immunodeficiencies all emerged from this foundational work. Each success demonstrated that when we target the root cause of a rare disease, we often learn principles that generalize far beyond it.

The 2010s introduced CRISPR and the arrival of programmable genome editing. Again, some of the first compelling human applications focused on rare monogenic conditions. Rare-disease researchers became early adopters, not because rare diseases are easier to treat—they aren’t—but because their clear genetic etiology offers an unusually precise testing ground. Knowledge gained through these trials now informs CRISPR-based approaches for cancer, cardiovascular disease, and autoimmune disorders.

By the early 2020s, the field reached a new threshold: curative intent. Gene therapies no longer promised only symptom management—they promised restoration of function, prevention of long-term complications, and, in some cases, normal lifespans. Meanwhile, consumer spending patterns remained unchanged. Society continued to spend hundreds of billions on waste, novelty, and disposables, even as the cures emerging from rare-disease science demonstrated returns that were moral, economic, and technological.

This 25-year arc reveals two truths. First: rare-disease research has consistently built the tools that propel all of medicine forward. Second: the scale of scientific progress has far outpaced the scale of societal investment. The science is ready for a great leap; the funding is still stuck in a model that treats rarity as a discount on human value.

Sidebar — Where the Money Goes: A Visual Thought Experiment

Imagine lining up eight buckets, each representing one major category of wasteful consumer spending: lottery tickets, food waste, unused subscriptions, disposable vapes, unnecessary phone upgrades, sugary drinks, gambling losses, and novelty purchases like pet costumes. Into these buckets flows approximately $550–$600 billion every year. The contents disappear. Nothing grows from them. Nothing compounds.

Now picture a ninth bucket labeled “Rare-Disease Research.” Into this bucket flows a single teaspoon by comparison—just a few billion dollars from federal grants, philanthropy, and industry research combined. And yet from this tiny bucket emerge gene therapies that restore neuromuscular function in children, CRISPR treatments that rewrite the history of pain for sickle cell patients, enzyme therapies that prevent neurological decline, and scientific platforms that reshape the very nature of what medicine can do.

The thought experiment is not meant to moralize individual behavior; it is meant to make the systemic imbalance visible. If even one bucket of waste were partially diverted—if a fraction of lottery spending, or a sliver of food waste, or a modest portion of unused subscription fees flowed into rare-disease science—the scientific and human returns would be transformative. The contrast invites a question every society eventually must ask: what would it mean to spend money in alignment with our values, rather than our habits?

Classroom Prompts

• Systems Misalignment: Choose one category of wasteful spending (lottery tickets, food waste, phone churn, sugary drinks). Map the feedback loops that keep the spending pattern in place. Then map the feedback loops that support underfunding of rare-disease research. Where are the leverage points for change?
• Value vs. Habit: Make two lists: (1) the societal benefits of rare-disease research and (2) the short-lived benefits of a high-volume consumer category. Discuss how societies can confuse habit-driven spending with value-driven investment.
• Ethics and Equity: Rare diseases often affect small populations. Should the size of a patient population influence how much society invests in their health? What ethical frameworks support your position?
• Opportunity Cost: If you could redirect just 1% of a wasteful spending category toward a rare-disease initiative, which category would you choose and why? What measurable impact would that redirection have over 10 years?

Annotated Sources

• National Academies of Sciences, Addressing Rare Diseases: A Human-Centered Approach. Offers an overview of the prevalence, economic burden, and diagnostic challenges of rare diseases, emphasizing systems-level inefficiencies and opportunities for intervention.
• National Institutes of Health (NIH), Genomic Medicine Progress Reports. Provides insight into how rare-disease research has driven advances in gene therapy, genome sequencing, and molecular diagnostics used across medicine.
• Global Economics of Food Waste, United States Department of Agriculture (USDA). Documents the scale and mechanisms of food waste, including financial, environmental, and operational impacts. Useful for contrasting negative-sum spending with high-return scientific investment.
• American Gaming Association, U.S. Gambling Revenue Reports. Presents financial data on gambling losses, illustrating a large-scale example of societal spending with no compounding return.
• FDA and EMA Gene Therapy Approvals Dossiers. Detail safety, efficacy, cost, and long-term value metrics for therapies such as Zolgensma, Luxturna, and CRISPR-based treatments. Demonstrate the societal ROI of rare-disease breakthroughs.
• Human Genome Project, Socioeconomic Impact Study. Shows how the original $2.7 billion investment returned nearly $800 billion in economic activity—an essential frame for the compounding value of rare-disease platforms.

© 2025 Michael A. Pink